Accelerate Diagnostics (AXDX) Misses Q2 EPS by 222c

Accelerate Diagnostics (NASDAQ: AXDX) reported Q2 EPS of ($2.36), $2.22 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $2.92 million versus the consensus estimate of $3.6 million.

For earnings history and earnings-related data on Accelerate Diagnostics (AXDX) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• Snail, Inc. sets 1-for-5 reverse stock split to meet Nasdaq rules
• AeroVironment (AVAV) Tops Q4 EPS by 36c